| Literature DB >> 22252901 |
Basar Candemir1, Mustafa Kilickap, Ozgur Ulas Ozcan, Cansin Tulunay Kaya, Menekse Gerede, Aydan Ongun Ozdemir, Cagdas Ozdol, Deniz Kumbasar, Cetin Erol.
Abstract
We aimed to examine whether intracoronary high-dose bolus of tirofiban plus maintenance would result in improved clinical outcome in STEMI patients undergoing primary PCI in this pilot trial. A total of 56 patients were enrolled to receive either intracoronary high-dose bolus plus maintenance (n = 34) or intravenous high-dose bolus plus maintenance (n = 22) of tirofiban. Pre and post intervention TIMI flow grades, myocardial blush grades, peak CKMB and troponin levels, time to peak CKMB and troponin, time to 50% ST resolution and major composite adverse cardiac event rates at 30 days were recorded. Although incidence of major adverse cardiac events was not different, post intervention TIMI flow and TIMI blush grades, peak CKMB and troponin levels, and time to peak CKMB and time to peak troponin were significantly different, favoring intracoronary strategy. In conclusion, this regimen improved myocardial reperfusion and coronary flow, and reduced myocardial necrosis, but failed to improve clinical outcomes at 30 days.Entities:
Mesh：
Substances：
Year: 2012 PMID： 22252901 DOI： 10.1007/s11239-012-0685-y
Source DB: PubMed Journal: J Thromb Thrombolysis ISSN： 0929-5305 Impact factor: 2.300